Summary

The CRISPR market is expected to reach USD 6.12 billion in 2031 from USD 3.48 billion in 2026, at a CAGR of 12.0% during the forecast period. Market growth is driven by the increasing adoption of CRISPR-based genome editing in drug discovery, functional genomics, cell and gene therapy, genetic disease research, and molecular diagnostics. Advancements in base editing, prime editing, RNA editing, and high-fidelity CRISPR systems are further expanding the range of genome-editing applications. Increasing demand for precise, scalable, and reproducible genome-editing workflows is also supporting the adoption of CRISPR products and services.

The CRISPR kits & enzymes segment is expected to grow at the highest CAGR during the forecast period
The CRISPR kits & enzymes segment is expected to grow at the highest CAGR during the forecast period, driven by increasing demand for ready-to-use genome-editing reagents and enzymes across research and genome-engineering workflows. These products support applications such as guide RNA-based editing, gene knockout, gene activation, editing validation, and development of advanced genome-editing systems. Growing adoption of high-throughput screening, functional genomics, and next-generation editors is increasing the need for specialized CRISPR kits and enzymes. Continued development of high-fidelity nucleases, base editors, prime editors, and other engineered editing systems is expected to further support demand for advanced CRISPR products.

The drug discovery & development segment holds the largest share of the market
The drug discovery & development segment holds the largest share of the CRISPR market, supported by the increasing use of genome editing for target identification, target validation, disease-model development, functional genomics, and drug screening. Pharmaceutical and biotechnology companies increasingly use CRISPR-based knockout, activation, inhibition, and screening approaches to investigate gene function and disease mechanisms and identify potential therapeutic targets. The growing use of CRISPR in cell and gene therapy development and precision medicine is further supporting demand for genome-editing products, screening platforms, and related services.

The US is expected to grow at the highest CAGR during the forecast period
The US is expected to grow at the highest CAGR in the CRISPR market due to its strong presence of leading genome-editing companies, advanced biomedical research infrastructure, and high adoption of CRISPR technologies across research and therapeutic applications. Rising use of CRISPR in drug discovery, functional genomics, cell and gene therapy, genetic disease research, and precision medicine is driving market growth. Technologies such as CRISPR-Cas systems, base editing, prime editing, guide RNA design, and genome-editing screening and validation are increasingly used across pharmaceutical companies, biotechnology firms, academic institutes, and research organizations, further supporting demand.

The primary interviews conducted for this report can be categorized as follows:
- By Respondent: Supply Side – 70% and Demand Side – 30%
- By Designation: Managers – 45%, CXOs and Directors – 30%, and Executives – 25%
- By Region: North America – 40%, Europe – 25%, Asia Pacific – 25%, Latin America – 5%, the Middle East & Africa – 5%

Thermo Fisher Scientific Inc. (US), Merck KGaA (Germany), Agilent Technologies, Inc. (US), GenScript (US), Takara Bio Inc. (Japan), Creative Biogene (US), Fujian SunvBiotech Co., Ltd. (China), EditCR (US), Caribou Biosciences, Inc. (US), Lonza (Switzerland), and Danaher Corporation (US) are some of the key companies offering CRISPR products and services.

Research Coverage
This research report categorizes the CRISPR market by offering (products and services), product type (CRISPR kits & enzymes, CRISPR libraries, and other products), product end user (pharmaceutical & biotechnology companies, academic & research institutes, and other end users), service type (gRNA synthesis & cell line development, screening & validation, and other services), service end user (pharmaceutical & biotechnology companies, academic & research institutes, and other end users), application (drug discovery & development, agriculture, and other applications), and region (North America, Europe, Asia Pacific, Latin America, and Middle East & Africa).

The report’s scope encompasses detailed information about the primary factors, including drivers, restraints, challenges, and opportunities, that influence the growth of the CRISPR market. A comprehensive analysis of key industry players provides insights into their business overview, product portfolio, key strategies, new product launches, acquisitions, and recent developments related to the CRISPR market. This report also includes a competitive analysis of emerging startups in the CRISPR industry ecosystem.

Key Benefits of Buying the Report
The report will assist market leaders and new entrants by providing revenue estimates for the overall market and its subsegments. It will also help stakeholders better understand the competitive landscape and gain more insights to position their businesses effectively and develop suitable go-to-market strategies. This report will enable stakeholders to grasp the market's pulse and offer information on key market drivers, restraints, opportunities, and challenges.

The report provides insights into the following pointers:
- Analysis of key drivers (growing demand for CRISPR-based gene therapies, advancements in CRISPR technology, growing government and private investments and funding for CRISPR technology), restraints (technical challenges associated with CRISPR technology), opportunities (development of new vaccines and treatments for genetic diseases, expanding industrial and agricultural applications of CRISPR), and challenges (regulatory hurdles for CRISPR advancements) influencing the market growth
- Product Development/Innovation: Detailed insights into newly launched products and innovations in the CRISPR market
- Market Development: Comprehensive information about lucrative markets and analysis of the market across varied regions
- Market Diversification: Exhaustive information about new products, untapped geographies, recent developments, and investments in the CRISPR market
- Competitive Assessment: In-depth assessment of market shares, growth strategies, and products of leading players, Thermo Fisher Scientific Inc. (US), Merck KGaA (Germany), Agilent Technologies, Inc. (US), GenScript (US), Takara Bio (Japan), Revvity (US), Danaher (US), and Lonza (Switzerland), among others, for the CRISPR market

ページTOPに戻る

Table of Contents

1 INTRODUCTION 29
1.1 STUDY OBJECTIVES 29
1.2 MARKET DEFINITION 29
1.3 STUDY SCOPE 30
1.3.1 MARKETS COVERED & REGIONAL SCOPE 30
1.3.2 INCLUSIONS & EXCLUSIONS 31
1.3.3 YEARS CONSIDERED 31
1.3.4 CURRENCY CONSIDERED 32
1.4 STAKEHOLDERS 32
1.5 SUMMARY OF CHANGES 32

2 EXECUTIVE SUMMARY 34
2.1 MARKET HIGHLIGHTS & KEY INSIGHTS 34
2.2 KEY MARKET PARTICIPANTS: MAPPING OF STRATEGIC DEVELOPMENTS 36
2.3 DISRUPTIVE TRENDS IN CRISPR MARKET 37
2.4 HIGH-GROWTH SEGMENTS 38
2.5 REGIONAL SNAPSHOT: MARKET SIZE, GROWTH RATE, AND FORECAST 39

3 PREMIUM INSIGHTS 40
3.1 CRISPR MARKET OVERVIEW 40
3.2 NORTH AMERICA: CRISPR MARKET, BY SERVICE 41
3.3 CRISPR MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES 41
3.4 CRISPR MARKET SHARE, BY OFFERING, 2026 VS. 2031 (%) 42

4 MARKET OVERVIEW 43
4.1 INTRODUCTION 43
4.2 MARKET DYNAMICS 43
4.2.1 DRIVERS 44
4.2.1.1 Growing demand for CRISPR-based gene therapies 44
4.2.1.2 Advancements in CRISPR technology 45
4.2.1.3 Growing government and private investments and funding for
CRISPR technology 46
4.2.2 RESTRAINTS 47
4.2.2.1 Technical challenges associated with CRISPR technology 47
4.2.3 OPPORTUNITIES 47
4.2.3.1 Development of new vaccines and treatments for genetic diseases 47
4.2.3.2 Expanding industrial and agricultural applications of CRISPR 48
4.2.4 CHALLENGES 48
4.2.4.1 Regulatory hurdles for CRISPR advancements 48
4.3 UNMET NEEDS & WHITE SPACES 49
4.4 INTERCONNECTED MARKETS & CROSS-SECTOR OPPORTUNITIES 49
4.5 STRATEGIC MOVES BY TIER-1/2/3 PLAYERS 50

5 INDUSTRY TRENDS 51
5.1 PORTER’S FIVE FORCES ANALYSIS 51
5.1.1 THREAT OF NEW ENTRANTS 52
5.1.2 THREAT OF SUBSTITUTES 52
5.1.3 BARGAINING POWER OF BUYERS 53
5.1.4 BARGAINING POWER OF SUPPLIERS 53
5.1.5 INTENSITY OF COMPETITIVE RIVALRY 53
5.2 MACROECONOMIC OUTLOOK 54
5.2.1 INTRODUCTION 54
5.2.2 GDP TRENDS & FORECAST 54
5.2.3 TRENDS IN GLOBAL HEALTHCARE INDUSTRY 55
5.2.4 TRENDS IN GLOBAL BIOTECH INDUSTRY 55
5.3 VALUE CHAIN ANALYSIS 56
5.4 ECOSYSTEM ANALYSIS 57
5.4.1 ROLE OF PLAYERS IN ECOSYSTEM 59
5.5 PRICING ANALYSIS 60
5.5.1 AVERAGE SELLING PRICE TREND OF CRISPR KITS & REAGENTS,
BY KEY PLAYER, 2023–2025 60
5.5.2 INDICATIVE PRICE TREND FOR CRISPR SERVICES 61
5.5.3 AVERAGE SELLING PRICE OF CRISPR KITS & REAGENTS, BY REGION, 2025 62
5.6 TRADE ANALYSIS 63
5.6.1 IMPORT SCENARIO (HS CODE 3822.00) 63
5.6.2 EXPORT SCENARIO (HS CODE 3822.00) 64
5.7 KEY CONFERENCES & EVENTS, 2026–2027 65
5.8 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES 66
5.9 INVESTMENT & FUNDING SCENARIO 67
5.10 CASE STUDY ANALYSIS 68
5.10.1 CRISPR-CAS9 EDITING DEMONSTRATES DURABLE LIPID REDUCTION 68
5.10.2 IN VIVO CRISPR EDITING SIGNIFICANTLY REDUCES HEREDITARY ANGIOEDEMA ATTACKS 68
5.11 IMPACT OF 2025 US TARIFFS ON CRISPR MARKET 69
5.11.1 INTRODUCTION 69
5.11.2 KEY TARIFF RATES 69
5.11.3 PRICE IMPACT ANALYSIS 71
5.11.4 IMPACT ON COUNTRY/REGION 71
5.11.4.1 US 71
5.11.4.2 Europe 72
5.11.4.3 Asia Pacific 72
5.11.4.4 Rest of the World 73
5.11.5 IMPACT ON END-USE INDUSTRIES 73
5.11.5.1 Pharmaceutical & biotech companies 73
5.11.5.2 Contract Research Organizations (CROs) 73
5.11.5.3 Academic & research institutes 74

6 TECHNOLOGICAL ADVANCEMENTS, AI-DRIVEN IMPACT, PATENTS, INNOVATIONS, AND FUTURE APPLICATIONS 75
6.1 TECHNOLOGY ANALYSIS 75
6.1.1 KEY TECHNOLOGIES 75
6.1.1.1 CRISPR-Cas systems 75
6.1.1.2 gRNA design & optimization 75
6.1.1.3 High-throughput CRISPR screening 76
6.1.2 COMPLEMENTARY TECHNOLOGIES 76
6.1.2.1 Synthetic biology 76
6.1.2.2 Single-cell genomics 77
6.1.2.3 Next-generation sequencing 77
6.1.3 ADJACENT TECHNOLOGIES 77
6.1.3.1 Stem cell engineering 77
6.1.3.2 Synthetic DNA & gene synthesis 78
6.1.3.3 Microfluidics 78
6.2 TECHNOLOGY ROADMAP 79
6.3 PATENT ANALYSIS 79
6.3.1 METHODOLOGY 79
6.3.2 NUMBER OF PATENTS FILED, BY DOCUMENT TYPE 79
6.3.3 LIST OF KEY PATENTS 81
6.4 FUTURE APPLICATIONS 82
6.5 IMPACT OF AI/GEN AI ON CRISPR MARKET 83
6.5.1 TOP USE CASES & MARKET POTENTIAL 84
6.5.2 BEST PRACTICES IN AI-ENABLED CRISPR WORKFLOWS 84
6.5.3 CASE STUDIES OF AI IMPLEMENTATION IN CRISPR MARKET 84
6.5.4 INTERCONNECTED ADJACENT ECOSYSTEM & IMPACT ON MARKET PLAYERS 85
6.5.5 CLIENTS’ READINESS TO ADOPT AI-INTEGRATED CRISPR TECHNOLOGIES 85

7 SUSTAINABILITY & REGULATORY LANDSCAPE 87
7.1 REGIONAL REGULATIONS & COMPLIANCE 87
7.1.1 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 87
7.1.2 INDUSTRY STANDARDS 92
7.1.2.1 North America 92
7.1.2.1.1 US 92
7.1.2.1.2 Canada 92
7.1.2.2 Europe 93
7.1.2.2.1 Germany 93
7.1.2.2.2 UK 93
7.1.2.2.3 France 93
7.1.2.3 Asia Pacific 94
7.1.2.3.1 Japan 94
7.1.2.3.2 China 94
7.1.2.4 Latin America 94
7.1.2.4.1 Brazil 94
7.1.2.5 Middle East & Africa 94
7.1.2.5.1 GCC Countries 94
7.1.2.5.2 South Africa 95
7.2 SUSTAINABILITY INITIATIVES 95
7.3 IMPACT OF REGULATORY POLICIES ON SUSTAINABILITY INITIATIVES 96
7.4 CERTIFICATIONS, LABELING, AND ECO-STANDARDS 96

8 CUSTOMER LANDSCAPE & BUYER BEHAVIOR 100
8.1 DECISION-MAKING PROCESS 100
8.2 BUYER STAKEHOLDERS & BUYING EVALUATION CRITERIA 100
8.2.1 KEY STAKEHOLDERS IN BUYING PROCESS 100
8.2.2 CRISPR MARKET: BUYING CRITERIA 101
8.3 ADOPTION BARRIERS & INTERNAL CHALLENGES 103
8.4 UNMET NEEDS FROM VARIOUS END-USE INDUSTRIES 104

9 CRISPR MARKET, BY OFFERING 105
9.1 INTRODUCTION 106
9.2 PRODUCTS 106
9.2.1 ADVANCEMENTS IN GENOME EDITING TO DRIVE GROWTH 106
9.3 SERVICES 109
9.3.1 GROWING DEMAND FOR PRECISE GENOME EDITING TOOLS IN RESEARCH AND CLINICAL APPLICATIONS TO BOOST MARKET 109

10 CRISPR PRODUCTS MARKET, BY TYPE 113
10.1 INTRODUCTION 114
10.2 CRISPR KITS & ENZYMES 114
10.2.1 CRISPR KITS & ENZYMES SEGMENT TO DOMINATE CRISPR PRODUCTS MARKET DURING FORECAST PERIOD 114
10.3 CRISPR LIBRARIES 117
10.3.1 INCREASING APPLICATIONS OF CRISPR LIBRARIES IN GENE EDITING TO DRIVE GROWTH 117
10.4 OTHER PRODUCTS 120

11 CRISPR PRODUCTS MARKET, BY END USER 123
11.1 INTRODUCTION 124
11.2 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES 124
11.2.1 INCREASING PRODUCT APPROVALS AND ROBUST CLINICAL PIPELINE TO PROPEL MARKET 124
11.3 ACADEMIC & RESEARCH INSTITUTES 127
11.3.1 INCREASING FUNDING FOR GENOMIC PROJECTS TO PROPEL MARKET 127
11.4 OTHER END USERS 130

12 CRISPR MARKET, BY SERVICE 133
12.1 INTRODUCTION 134
12.1.1 GRNA SYNTHESIS & CELL LINE DEVELOPMENT 134
12.1.1.1 Emerging opportunities in CRISPR gRNA synthesis & cell line development to drive growth 134
12.1.2 SCREENING & VALIDATION 137
12.1.2.1 Rapid advancements in CRISPR technology to drive growth 137
12.2 OTHER SERVICES 140

13 CRISPR SERVICES MARKET, BY END USER 143
13.1 INTRODUCTION 144
13.2 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES 144
13.2.1 ADVANCEMENTS IN GENOME EDITING TO DRIVE GROWTH 144
13.3 ACADEMIC & RESEARCH INSTITUTES 147
13.3.1 INCREASING INVESTMENTS IN GENOMIC PROJECTS TO PROPEL MARKET 147
13.4 OTHER END USERS 150

14 CRISPR MARKET, BY APPLICATION 153
14.1 INTRODUCTION 154
14.2 DRUG DISCOVERY & DEVELOPMENT 154
14.2.1 ADVANCEMENTS IN GENOME EDITING TO DRIVE GROWTH 154
14.3 AGRICULTURE 157
14.3.1 GROWING DEMAND FOR ENHANCED CROP TRAITS TO DRIVE GROWTH 157
14.4 OTHER APPLICATIONS 160

15 CRISPR MARKET, BY REGION 163
15.1 INTRODUCTION 164
15.2 NORTH AMERICA 164
15.2.1 US 167
15.2.1.1 Increasing demand for CRISPR products and services across various industries to drive growth 167
15.2.2 CANADA 170
15.2.2.1 Increasing demand for gene-editing technologies to boost growth 170
15.3 EUROPE 172
15.3.1 GERMANY 175
15.3.1.1 Rapidly increasing biotechnology sector to support growth 175
15.3.2 UK 177
15.3.2.1 Significant government investments in genomics research to propel growth 177
15.3.3 FRANCE 179
15.3.3.1 Increasing demand for targeted therapies and personalized medicine to propel growth 179
15.3.4 ITALY 182
15.3.4.1 Increasing demand for innovative therapeutic solutions to drive growth 182
15.3.5 SPAIN 184
15.3.5.1 Increasing demand for precision medicine to drive growth 184
15.3.6 REST OF EUROPE 187
15.4 ASIA PACIFIC 189
15.4.1 CHINA 192
15.4.1.1 Increasing investments in R&D to drive growth 192
15.4.2 JAPAN 195
15.4.2.1 Potential of CRISPR-based therapies in personalized medicine to present opportunities for market growth 195
15.4.3 INDIA 197
15.4.3.1 Increasing prevalence of genetic disorders to support growth 197
15.4.4 AUSTRALIA 200
15.4.4.1 Growing clinical translation and advancements in CRISPR technologies to support growth 200
15.4.5 SOUTH KOREA 202
15.4.5.1 Advancements in next-generation CRISPR and precision RNA editing to support growth 202
15.4.6 REST OF ASIA PACIFIC 204
15.5 LATIN AMERICA 207
15.5.1 BRAZIL 209
15.5.1.1 Growing adoption of genome technologies to propel growth 209
15.5.2 REST OF LATIN AMERICA 211
15.6 MIDDLE EAST 213
15.6.1 GCC COUNTRIES 216
15.6.1.1 Saudi Arabia 219
15.6.1.1.1 Regulatory support and expanding advanced-therapy infrastructure to boost market 219
15.6.1.2 UAE 221
15.6.1.2.1 Precision medicine investment and advanced clinical infrastructure to aid market growth 221
15.6.1.3 Rest of GCC Countries 223
15.6.2 REST OF MIDDLE EAST 226
15.7 AFRICA 228
15.7.1 EXPANDING AGRICULTURAL BIOTECHNOLOGY AND GENOMICS RESEARCH TO PROPEL MARKET 228

16 COMPETITIVE LANDSCAPE 231
16.1 INTRODUCTION 231
16.2 KEY PLAYER STRATEGY/RIGHT TO WIN, JANUARY 2023–SEPTEMBER 2026 231
16.2.1 OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS IN CRISPR MARKET, JANUARY 2023–SEPTEMBER 2026 231
16.3 REVENUE ANALYSIS, 2021–2025 233
16.4 MARKET SHARE ANALYSIS, 2025 233
16.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2025 235
16.5.1 STARS 235
16.5.2 EMERGING LEADERS 235
16.5.3 PERVASIVE PLAYERS 236
16.5.4 PARTICIPANTS 236
16.5.5 COMPANY FOOTPRINT: KEY PLAYERS, 2025 237
16.5.5.1 Company footprint 237
16.5.5.2 Region footprint 237
16.5.5.3 Product footprint 238
16.5.5.4 Service footprint 238
16.5.5.5 Application footprint 239
16.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2025 240
16.6.1 PROGRESSIVE COMPANIES 240
16.6.2 RESPONSIVE COMPANIES 240
16.6.3 DYNAMIC COMPANIES 240
16.6.4 STARTING BLOCKS 240
16.6.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES 242
16.6.5.1 Detailed list of key startups/SMEs 242
16.6.5.2 Competitive benchmarking of key startups/SMEs 243
16.7 COMPANY VALUATION & FINANCIAL METRICS 244
16.7.1 COMPANY VALUATION & FINANCIAL METRICS 244
16.7.2 COMPANY VALUATION & FINANCIAL METRICS 244
16.8 BRAND COMPARISON 245
16.9 COMPETITIVE SCENARIO 246
16.9.1 PRODUCT LAUNCHES 246
16.9.2 DEALS 247
16.9.3 EXPANSIONS 248

17 COMPANY PROFILES 249
17.1 KEY PLAYERS 249
17.1.1 THERMO FISHER SCIENTIFIC INC. 249
17.1.1.1 Business overview 249
17.1.1.2 Products & services offered 250
17.1.1.3 Recent developments 252
17.1.1.3.1 Expansions 252
17.1.1.4 MnM view 252
17.1.1.4.1 Key strengths 252
17.1.1.4.2 Strategic choices 252
17.1.1.4.3 Weaknesses & competitive threats 252
17.1.2 MERCK KGAA 253
17.1.2.1 Business overview 253
17.1.2.2 Products & services offered 254
17.1.2.3 Recent developments 255
17.1.2.3.1 Product launches 255
17.1.2.3.2 Deals 256
17.1.2.4 MnM view 256
17.1.2.4.1 Key strengths 256
17.1.2.4.2 Strategic choices 256
17.1.2.4.3 Weaknesses & competitive threats 256
17.1.3 AGILENT TECHNOLOGIES, INC. 257
17.1.3.1 Business overview 257
17.1.3.2 Products & services offered 258
17.1.3.3 Recent developments 259
17.1.3.3.1 Deals 259
17.1.3.3.2 Expansions 259
17.1.3.4 MnM view 260
17.1.3.4.1 Key strengths 260
17.1.3.4.2 Strategic choices 260
17.1.3.4.3 Weaknesses & competitive threats 260
17.1.4 GENSCRIPT 261
17.1.4.1 Business overview 261
17.1.4.2 Products & services offered 262
17.1.4.3 Recent developments 264
17.1.4.3.1 Deals 264
17.1.4.3.2 Expansions 264
17.1.4.4 MnM view 265
17.1.4.4.1 Key strengths 265
17.1.4.4.2 Strategic choices 265
17.1.4.4.3 Weaknesses & competitive threats 265
17.1.5 REVVITY 266
17.1.5.1 Business overview 266
17.1.5.2 Products & services offered 267
17.1.5.3 Recent developments 269
17.1.5.3.1 Product launches 269
17.1.5.3.2 Deals 269
17.1.6 LONZA 271
17.1.6.1 Business overview 271
17.1.6.2 Products & services offered 272
17.1.6.3 Recent developments 273
17.1.6.3.1 Product launches 273
17.1.6.3.2 Deals 273
17.1.6.3.3 Expansions 273
17.1.7 DANAHER CORPORATION 274
17.1.7.1 Business overview 274
17.1.7.2 Products & services offered 275
17.1.7.3 Recent developments 276
17.1.7.3.1 Product launches 276
17.1.7.3.2 Deals 276
17.1.8 TAKARA BIO INC. 277
17.1.8.1 Business overview 277
17.1.8.2 Products & services offered 278
17.1.8.3 Recent developments 279
17.1.8.3.1 Deals 279
17.1.9 CREATIVE BIOGENE 280
17.1.9.1 Business overview 280
17.1.9.2 Products & services offered 280
17.1.9.3 Recent developments 281
17.1.9.3.1 Service launches 281
17.1.10 FUJIAN SUNYBIOTECH CO., LTD. 282
17.1.10.1 Business overview 282
17.1.10.2 Products & services offered 282
17.1.11 EDITCO 283
17.1.11.1 Business overview 283
17.1.11.2 Products & services offered 283
17.1.11.3 Recent financials 284
17.1.11.3.1 Deals 284
17.1.12 CARIBOU BIOSCIENCES, INC. 285
17.1.12.1 Business overview 285
17.1.12.2 Products & services offered 286
17.1.12.3 Recent developments 286
17.1.12.3.1 Deals 286
17.1.13 DEMEETRA AGBIO 287
17.1.13.1 Business overview 287
17.1.13.2 Products & services offered 287
17.1.13.3 Recent developments 287
17.1.13.3.1 Deals 287
17.1.14 ORIGENE TECHNOLOGIES, INC. 288
17.1.14.1 Business overview 288
17.1.14.2 Products & services offered 288
17.1.15 CELLECTA, INC. 289
17.1.15.1 Business overview 289
17.1.15.2 Products & services offered 289
17.2 OTHER PLAYERS 291
17.2.1 MAMMOTH BIOSCIENCES, INC. 291
17.2.2 APPLIED STEMCELL 291
17.2.3 NEW ENGLAND BIOLABS 292
17.2.4 TOOLGEN, INC. 293
17.2.5 GENECOPOEIA, INC. 294
17.2.6 TWIST BIOSCIENCE 295
17.2.7 SYNTHEGO 296
17.2.8 EGENESIS 297
17.2.9 MANUS BIO 297
17.2.10 PRECISION BIOSCIENCES 298

18 RESEARCH METHODOLOGY 299
18.1 RESEARCH DATA 299
18.1.1 SECONDARY DATA 299
18.1.2 PRIMARY RESEARCH 300
18.2 MARKET SIZE ESTIMATION 302
18.2.1 GLOBAL MARKET ESTIMATION 302
18.2.1.1 Insights from primary experts 305
18.2.2 SEGMENTAL MARKET ESTIMATION (TOP-DOWN APPROACH) 306
18.3 MARKET GROWTH RATE PROJECTION 307
18.4 DATA TRIANGULATION 309
18.5 RESEARCH ASSUMPTIONS 310
18.6 RESEARCH LIMITATIONS 311
18.7 RISK ANALYSIS 311

19 APPENDIX 312
19.1 DISCUSSION GUIDE 312
19.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 315
19.3 CUSTOMIZATION OPTIONS 317
19.4 RELATED REPORTS 317
19.5 AUTHOR DETAILS 318

ページTOPに戻る

List of Tables/Graphs

FIGURE 1 CRISPR MARKET SEGMENTATION & REGIONAL SCOPE 30.
FIGURE 2 MARKET SCENARIO 34.
FIGURE 3 GLOBAL CRISPR MARKET, 2023–2031 35.
FIGURE 4 MAJOR STRATEGIES ADOPTED BY KEY PLAYERS IN CRISPR MARKET, 2023–2026 36.
FIGURE 5 DISRUPTIONS INFLUENCING GROWTH OF CRISPR MARKET 37.
FIGURE 6 HIGH-GROWTH SEGMENTS IN CRISPR MARKET, 2026–2031 38.
FIGURE 7 ASIA PACIFIC TO REGISTER HIGHEST CAGR IN CRISPR MARKET, IN TERMS OF VALUE, DURING FORECAST PERIOD 39.
FIGURE 8 GROWING INVESTMENTS IN CRISPR TECHNOLOGY AND EXPANDING APPLICATIONS TO DRIVE MARKET GROWTH 40.
FIGURE 9 PRODUCTS ACCOUNTED FOR LARGEST SHARE OF CRISPR MARKET.
IN NORTH AMERICA IN 2025 41.
FIGURE 10 CHINA TO BE FASTEST-GROWING MARKET IN GLOBAL CRISPR MARKET DURING FORECAST PERIOD 41.
FIGURE 11 PRODUCTS SEGMENT TO DOMINATE MARKET DURING FORECAST PERIOD 42.
FIGURE 12 CRISPR MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES 43.
FIGURE 13 TOP 10 LEADING CRISPR STARTUPS BASED ON INVESTMENTS RAISED IN 2024 46.
FIGURE 14 CRISPR MARKET: PORTER’S FIVE FORCES ANALYSIS 51.
FIGURE 15 CRISPR MARKET: VALUE CHAIN ANALYSIS 56.
FIGURE 16 CRISPR MARKET: ECOSYSTEM ANALYSIS 58.
FIGURE 17 AVERAGE SELLING PRICE OF CRISPR KITS & REAGENTS, BY KEY PLAYER (2025) 61.
FIGURE 18 AVERAGE SELLING PRICE OF CRISPR KITS & REAGENTS, BY REGION, 2025 (USD) 63.
FIGURE 19 CRISPR MARKET: TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES 66.
FIGURE 20 INVESTMENT & FUNDING SCENARIO, 2023–2025 (USD MILLION) 68.
FIGURE 21 PATENT APPLICATIONS IN CRISPR MARKET, JANUARY 2015–DECEMBER 2025 80.
FIGURE 22 IMPACT OF AI/GEN AI ON CRISPR MARKET 83.
FIGURE 23 INFLUENCE OF KEY STAKEHOLDERS ON BUYING PROCESS, BY OFFERING 100.
FIGURE 24 KEY BUYING CRITERIA OF END USERS FOR CRISPR PRODUCTS 101.
FIGURE 25 KEY SELECTION CRITERIA OF END USERS FOR CRISPR SERVICES 101.
FIGURE 26 NORTH AMERICA: CRISPR MARKET SNAPSHOT 165.
FIGURE 27 ASIA PACIFIC: CRISPR MARKET SNAPSHOT 189.
FIGURE 28 REVENUE ANALYSIS OF KEY PLAYERS IN CRISPR MARKET, 2021–2025 233.
FIGURE 29 MARKET SHARE ANALYSIS OF KEY PLAYERS IN CRISPR MARKET, 2025 234.
FIGURE 30 CRISPR MARKET: COMPANY EVALUATION MATRIX (KEY PLAYERS), 2025 236.
FIGURE 31 CRISPR MARKET: COMPANY FOOTPRINT 237.
FIGURE 32 CRISPR MARKET: COMPANY EVALUATION MATRIX (STARTUPS/SMES), 2025 241.
FIGURE 33 YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK.
BETA OF KEY VENDORS 244.
FIGURE 34 EV/EBITDA OF KEY VENDORS 244.
FIGURE 35 CRISPR MARKET: BRAND COMPARISON 245.
FIGURE 36 THERMO FISHER SCIENTIFIC INC.: COMPANY SNAPSHOT (2025) 250.
FIGURE 37 MERCK KGAA: COMPANY SNAPSHOT (2025) 254.
FIGURE 38 AGILENT TECHNOLOGIES, INC.: COMPANY SNAPSHOT (2025) 258.
FIGURE 39 GENSCRIPT: COMPANY SNAPSHOT (2025) 262.
FIGURE 40 REVVITY: COMPANY SNAPSHOT (2025) 267.
FIGURE 41 LONZA: COMPANY SNAPSHOT (2025) 272.
FIGURE 42 DANAHER CORPORATION: COMPANY SNAPSHOT (2025) 275.
FIGURE 43 TAKARA BIO INC.: COMPANY SNAPSHOT (2024) 278.
FIGURE 44 CARIBOU BIOSCIENCES, INC.: COMPANY SNAPSHOT (2025) 285.
FIGURE 45 CRISPR MARKET: RESEARCH DESIGN 299.
FIGURE 46 CRISPR MARKET: BREAKDOWN OF PRIMARY INTERVIEWS 301.
FIGURE 47 CRISPR MARKET SIZE ESTIMATION (SUPPLY-SIDE ANALYSIS), 2025 302.
FIGURE 48 CRISPR MARKET ESTIMATION: APPROACH 1 (COMPANY REVENUE.
ANALYSIS-BASED ESTIMATION), 2025 303.
FIGURE 49 ILLUSTRATIVE EXAMPLE OF THERMO FISHER SCIENTIFIC INC.:.
REVENUE SHARE ANALYSIS (2025) 303.
FIGURE 50 MARKET SIZE VALIDATION FROM PRIMARY SOURCES 305.
FIGURE 51 SEGMENTAL MARKET SIZE ESTIMATION METHODOLOGY: TOP-DOWN APPROACH 306.
FIGURE 52 CRISPR MARKET: CAGR PROJECTIONS 308.
FIGURE 53 DATA TRIANGULATION METHODOLOGY 309.
TABLE 1 CRISPR MARKET: IMPACT ANALYSIS 44.
TABLE 2 CRISPR MARKET: PORTER’S FIVE FORCES ANALYSIS 52.
TABLE 3 CRISPR MARKET: ROLE OF PLAYERS IN ECOSYSTEM 59.
TABLE 4 AVERAGE SELLING PRICE TREND OF CRISPR KITS & REAGENTS, BY KEY PLAYER, 2023–2025 60.
TABLE 5 AVERAGE SELLING PRICE OF CRISPR KITS & REAGENTS, BY REGION, 2025 (USD) 62.
TABLE 6 IMPORT DATA FOR HS CODE 3822.00-COMPLIANT PRODUCTS, BY COUNTRY, 2021–2025 (USD THOUSAND) 63.
TABLE 7 EXPORT DATA FOR HS CODE 3822.00-COMPLIANT PRODUCTS, BY COUNTRY, 2021–2025 (USD THOUSAND) 64.
TABLE 8 CRISPR MARKET: KEY CONFERENCES & EVENTS, 2026–2027 65.
TABLE 9 RECIPROCAL TARIFF RATES ADJUSTED BY US 69.
TABLE 10 KEY TARIFFS ON PHARMACEUTICAL PRODUCTS 70.
TABLE 11 CRITICAL COMPONENTS LIKELY EXPOSED TO TARIFF CHANGES 71.
TABLE 12 NUMBER OF PATENTS FILED, BY DOCUMENT TYPE, 2015–2025 79.
TABLE 13 LIST OF KEY PATENTS IN CRISPR MARKET, 2023–2025 81.
TABLE 14 CASE STUDIES OF AI IMPLEMENTATION IN CRISPR MARKET 84.
TABLE 15 CLIENTS’ READINESS TO ADOPT AI-INTEGRATED CRISPR TECHNOLOGIES 86.
TABLE 16 NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 87.
TABLE 17 EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 88.
TABLE 18 ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 90.
TABLE 19 LATIN AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 91.
TABLE 20 MIDDLE EAST & AFRICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 91.
TABLE 21 INFLUENCE OF KEY STAKEHOLDERS ON BUYING PROCESS, BY OFFERING 101.
TABLE 22 KEY BUYING CRITERIA, BY END USER (PRODUCTS) 102.
TABLE 23 KEY BUYING CRITERIA, BY END USER (SERVICES) 102.
TABLE 24 CRISPR MARKET, BY OFFERING, 2023–2031 (USD MILLION) 106.
TABLE 25 CRISPR PRODUCTS MARKET, BY REGION, 2023–2031 (USD MILLION) 107.
TABLE 26 NORTH AMERICA: CRISPR PRODUCTS MARKET, BY COUNTRY,.
2023–2031 (USD MILLION) 107.
TABLE 27 EUROPE: CRISPR PRODUCTS MARKET, BY COUNTRY, 2023–2031 (USD MILLION) 107.
TABLE 28 ASIA PACIFIC: CRISPR PRODUCTS MARKET, BY COUNTRY,.
2023–2031 (USD MILLION) 108.
TABLE 29 LATIN AMERICA: CRISPR PRODUCTS MARKET, BY COUNTRY,.
2023–2031 (USD MILLION) 108.
TABLE 30 MIDDLE EAST: CRISPR PRODUCTS MARKET, BY REGION,.
2023–2031 (USD MILLION) 108.
TABLE 31 GCC COUNTRIES: CRISPR PRODUCTS MARKET, BY COUNTRY,.
2023–2031 (USD MILLION) 109.
TABLE 32 CRISPR SERVICES MARKET, BY REGION, 2023–2031 (USD MILLION) 110.
TABLE 33 NORTH AMERICA: CRISPR SERVICES MARKET, BY COUNTRY,.
2023–2031 (USD MILLION) 110.
TABLE 34 EUROPE: CRISPR SERVICES MARKET, BY COUNTRY, 2023–2031 (USD MILLION) 110.
TABLE 35 ASIA PACIFIC: CRISPR SERVICES MARKET, BY COUNTRY,.
2023–2031 (USD MILLION) 111.
TABLE 36 LATIN AMERICA: CRISPR SERVICES MARKET, BY COUNTRY,.
2023–2031 (USD MILLION) 111.
TABLE 37 MIDDLE EAST: CRISPR SERVICES MARKET, BY REGION,.
2023–2031 (USD MILLION) 111.
TABLE 38 GCC COUNTRIES: CRISPR SERVICES MARKET, BY COUNTRY,.
2023–2031 (USD MILLION) 112.
TABLE 39 CRISPR PRODUCTS MARKET, BY TYPE, 2023–2031 (USD MILLION) 114.
TABLE 40 CRISPR KITS & ENZYMES MARKET, BY REGION, 2023–2031 (USD MILLION) 115.
TABLE 41 NORTH AMERICA: CRISPR KITS & ENZYMES MARKET, BY COUNTRY,.
2023–2031 (USD MILLION) 115.
TABLE 42 EUROPE: CRISPR KITS & ENZYMES MARKET, BY COUNTRY,.
2023–2031 (USD MILLION) 115.
TABLE 43 ASIA PACIFIC: CRISPR KITS & ENZYMES MARKET, BY COUNTRY,.
2023–2031 (USD MILLION) 116.
TABLE 44 LATIN AMERICA: CRISPR KITS & ENZYMES MARKET, BY COUNTRY,.
2023–2031 (USD MILLION) 116.
TABLE 45 MIDDLE EAST: CRISPR KITS & ENZYMES MARKET, BY REGION,.
2023–2031 (USD MILLION) 116.
TABLE 46 GCC COUNTRIES: CRISPR KITS & ENZYMES MARKET, BY COUNTRY,.
2023–2031 (USD MILLION) 117.
TABLE 47 CRISPR LIBRARIES MARKET, BY REGION, 2023–2031 (USD MILLION) 118.
TABLE 48 NORTH AMERICA: CRISPR LIBRARIES MARKET, BY COUNTRY,.
2023–2031 (USD MILLION) 118.
TABLE 49 EUROPE: CRISPR LIBRARIES MARKET, BY COUNTRY, 2023–2031 (USD MILLION) 118.
TABLE 50 ASIA PACIFIC: CRISPR LIBRARIES MARKET, BY COUNTRY,.
2023–2031 (USD MILLION) 119.
TABLE 51 LATIN AMERICA: CRISPR LIBRARIES MARKET, BY COUNTRY,.
2023–2031 (USD MILLION) 119.
TABLE 52 MIDDLE EAST: CRISPR LIBRARIES MARKET, BY REGION,.
2023–2031 (USD MILLION) 119.
TABLE 53 GCC COUNTRIES: CRISPR LIBRARIES MARKET, BY COUNTRY,.
2023–2031 (USD MILLION) 120.
TABLE 54 OTHER CRISPR PRODUCTS MARKET, BY REGION, 2023–2031 (USD MILLION) 120.
TABLE 55 NORTH AMERICA: OTHER CRISPR PRODUCTS MARKET, BY COUNTRY,.
2023–2031 (USD MILLION) 121.
TABLE 56 EUROPE: OTHER CRISPR PRODUCTS MARKET, BY COUNTRY,.
2023–2031 (USD MILLION) 121.
TABLE 57 ASIA PACIFIC: OTHER CRISPR PRODUCTS MARKET, BY COUNTRY,.
2023–2031 (USD MILLION) 121.
TABLE 58 LATIN AMERICA: OTHER CRISPR PRODUCTS MARKET, BY COUNTRY,.
2023–2031 (USD MILLION) 122.
TABLE 59 MIDDLE EAST: OTHER CRISPR PRODUCTS MARKET, BY REGION,.
2023–2031 (USD MILLION) 122.
TABLE 60 GCC COUNTRIES: OTHER CRISPR PRODUCTS MARKET, BY COUNTRY,.
2023–2031 (USD MILLION) 122.
TABLE 61 CRISPR PRODUCTS MARKET, BY END USER, 2023–2031 (USD MILLION) 124.
TABLE 62 CRISPR PRODUCTS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2023–2031 (USD MILLION) 125.
TABLE 63 NORTH AMERICA: CRISPR PRODUCTS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2023–2031 (USD MILLION) 125.
TABLE 64 EUROPE: CRISPR PRODUCTS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2023–2031 (USD MILLION) 125.
TABLE 65 ASIA PACIFIC: CRISPR PRODUCTS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2023–2031 (USD MILLION) 126.
TABLE 66 LATIN AMERICA: CRISPR PRODUCTS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2023–2031 (USD MILLION) 126.
TABLE 67 MIDDLE EAST: CRISPR PRODUCTS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2023–2031 (USD MILLION) 126.
TABLE 68 GCC COUNTRIES: CRISPR PRODUCTS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2023–2031 (USD MILLION) 127.
TABLE 69 CRISPR PRODUCTS MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2023–2031 (USD MILLION) 127.
TABLE 70 NORTH AMERICA: CRISPR PRODUCTS MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2023–2031 (USD MILLION) 128.
TABLE 71 EUROPE: CRISPR PRODUCTS MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2023–2031 (USD MILLION) 128.
TABLE 72 ASIA PACIFIC: CRISPR PRODUCTS MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2023–2031 (USD MILLION) 128.
TABLE 73 LATIN AMERICA: CRISPR PRODUCTS MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2023–2031 (USD MILLION) 129.
TABLE 74 MIDDLE EAST: CRISPR PRODUCTS MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2023–2031 (USD MILLION) 129.
TABLE 75 GCC COUNTRIES: CRISPR PRODUCTS MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2023–2031 (USD MILLION) 129.
TABLE 76 CRISPR PRODUCTS MARKET FOR OTHER END USERS, BY REGION,.
2023–2031 (USD MILLION) 130.
TABLE 77 NORTH AMERICA: CRISPR PRODUCTS MARKET FOR OTHER END USERS,.
BY COUNTRY, 2023–2031 (USD MILLION) 130.
TABLE 78 EUROPE: CRISPR PRODUCTS MARKET FOR OTHER END USERS, BY COUNTRY, 2023–2031 (USD MILLION) 131.
TABLE 79 ASIA PACIFIC: CRISPR PRODUCTS MARKET FOR OTHER END USERS, BY COUNTRY, 2023–2031 (USD MILLION) 131.
TABLE 80 LATIN AMERICA: CRISPR PRODUCTS MARKET FOR OTHER END USERS,.
BY COUNTRY, 2023–2031 (USD MILLION) 131.
TABLE 81 MIDDLE EAST: CRISPR PRODUCTS MARKET FOR OTHER END USERS, BY REGION, 2023–2031 (USD MILLION) 132.
TABLE 82 GCC COUNTRIES: CRISPR PRODUCTS MARKET FOR OTHER END USERS,.
BY COUNTRY, 2023–2031 (USD MILLION) 132.
TABLE 83 CRISPR MARKET, BY SERVICE, 2023–2031 (USD MILLION) 134.
TABLE 84 CRISPR SERVICES MARKET FOR GRNA SYNTHESIS & CELL LINE DEVELOPMENT, BY REGION, 2023–2031 (USD MILLION) 135.
TABLE 85 NORTH AMERICA: CRISPR SERVICES MARKET FOR GRNA SYNTHESIS & CELL LINE DEVELOPMENT, BY COUNTRY, 2023–2031 (USD MILLION) 135.
TABLE 86 EUROPE: CRISPR SERVICES MARKET FOR GRNA SYNTHESIS & CELL LINE DEVELOPMENT, BY COUNTRY, 2023–2031 (USD MILLION) 135.
TABLE 87 ASIA PACIFIC: CRISPR SERVICES MARKET FOR GRNA SYNTHESIS & CELL LINE DEVELOPMENT, BY COUNTRY, 2023–2031 (USD MILLION) 136.
TABLE 88 LATIN AMERICA: CRISPR SERVICES MARKET FOR GRNA SYNTHESIS & CELL LINE DEVELOPMENT, BY COUNTRY, 2023–2031 (USD MILLION) 136.
TABLE 89 MIDDLE EAST: CRISPR SERVICES MARKET FOR GRNA SYNTHESIS & CELL LINE DEVELOPMENT, BY REGION, 2023–2031 (USD MILLION) 136.
TABLE 90 GCC COUNTRIES: CRISPR SERVICES MARKET FOR GRNA SYNTHESIS & CELL LINE DEVELOPMENT, BY COUNTRY, 2023–2031 (USD MILLION) 137.
TABLE 91 CRISPR SERVICES MARKET FOR SCREENING & VALIDATION, BY REGION,.
2023–2031 (USD MILLION) 138.
TABLE 92 NORTH AMERICA: CRISPR SERVICES MARKET FOR SCREENING & VALIDATION,.
BY COUNTRY, 2023–2031 (USD MILLION) 138.
TABLE 93 EUROPE: CRISPR SERVICES MARKET FOR SCREENING & VALIDATION,.
BY COUNTRY, 2023–2031 (USD MILLION) 138.
TABLE 94 ASIA PACIFIC: CRISPR SERVICES MARKET FOR SCREENING & VALIDATION,.
BY COUNTRY, 2023–2031 (USD MILLION) 139.
TABLE 95 LATIN AMERICA: CRISPR SERVICES MARKET FOR SCREENING & VALIDATION,.
BY COUNTRY, 2023–2031 (USD MILLION) 139.
TABLE 96 MIDDLE EAST: CRISPR SERVICES MARKET FOR SCREENING & VALIDATION,.
BY REGION, 2023–2031 (USD MILLION) 139.
TABLE 97 GCC COUNTRIES: CRISPR SERVICES MARKET FOR SCREENING & VALIDATION,.
BY COUNTRY, 2023–2031 (USD MILLION) 140.
TABLE 98 OTHER CRISPR SERVICES MARKET, BY REGION, 2023–2031 (USD MILLION) 140.
TABLE 99 NORTH AMERICA: OTHER CRISPR SERVICES MARKET, BY COUNTRY,.
2023–2031 (USD MILLION) 141.
TABLE 100 EUROPE: OTHER CRISPR SERVICES MARKET, BY COUNTRY,.
2023–2031 (USD MILLION) 141.
TABLE 101 ASIA PACIFIC: OTHER CRISPR SERVICES MARKET, BY COUNTRY,.
2023–2031 (USD MILLION) 141.
TABLE 102 LATIN AMERICA: OTHER CRISPR SERVICES MARKET, BY COUNTRY,.
2023–2031 (USD MILLION) 142.
TABLE 103 MIDDLE EAST: OTHER CRISPR SERVICES MARKET, BY REGION,.
2023–2031 (USD MILLION) 142.
TABLE 104 GCC COUNTRIES: OTHER CRISPR SERVICES MARKET, BY COUNTRY,.
2023–2031 (USD MILLION) 142.
TABLE 105 CRISPR SERVICES MARKET, BY END USER, 2023–2031 (USD MILLION) 144.
TABLE 106 CRISPR SERVICES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2023–2031 (USD MILLION) 145.
TABLE 107 NORTH AMERICA: CRISPR SERVICES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2023–2031 (USD MILLION) 145.
TABLE 108 EUROPE: CRISPR SERVICES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2023–2031 (USD MILLION) 145.
TABLE 109 ASIA PACIFIC: CRISPR SERVICES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2023–2031 (USD MILLION) 146.
TABLE 110 LATIN AMERICA: CRISPR SERVICES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2023–2031 (USD MILLION) 146.
TABLE 111 MIDDLE EAST: CRISPR SERVICES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2023–2031 (USD MILLION) 146.
TABLE 112 GCC COUNTRIES: CRISPR SERVICES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2023–2031 (USD MILLION) 147.
TABLE 113 CRISPR SERVICES MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2023–2031 (USD MILLION) 148.
TABLE 114 NORTH AMERICA: CRISPR SERVICES MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2023–2031 (USD MILLION) 148.
TABLE 115 EUROPE: CRISPR SERVICES MARKET FOR ACADEMIC & RESEARCH INSTITUTES,.
BY COUNTRY, 2023–2031 (USD MILLION) 148.
TABLE 116 ASIA PACIFIC: CRISPR SERVICES MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2023–2031 (USD MILLION) 149.
TABLE 117 LATIN AMERICA: CRISPR SERVICES MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2023–2031 (USD MILLION) 149.
TABLE 118 MIDDLE EAST: CRISPR SERVICES MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2023–2031 (USD MILLION) 149.
TABLE 119 GCC COUNTRIES: CRISPR SERVICES MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2023–2031 (USD MILLION) 150.
TABLE 120 CRISPR SERVICES MARKET FOR OTHER END USERS, BY REGION,.
2023–2031 (USD MILLION) 150.
TABLE 121 NORTH AMERICA: CRISPR SERVICES MARKET FOR OTHER END USERS,.
BY COUNTRY, 2023–2031 (USD MILLION) 151.
TABLE 122 EUROPE: CRISPR SERVICES MARKET FOR OTHER END USERS, BY COUNTRY, 2023–2031 (USD MILLION) 151.
TABLE 123 ASIA PACIFIC: CRISPR SERVICES MARKET FOR OTHER END USERS, BY COUNTRY, 2023–2031 (USD MILLION) 151.
TABLE 124 LATIN AMERICA: CRISPR SERVICES MARKET FOR OTHER END USERS,.
BY COUNTRY, 2023–2031 (USD MILLION) 152.
TABLE 125 MIDDLE EAST: CRISPR SERVICES MARKET FOR OTHER END USERS,.
BY REGION, 2023–2031 (USD MILLION) 152.
TABLE 126 GCC COUNTRIES: CRISPR SERVICES MARKET FOR OTHER END USERS,.
BY COUNTRY, 2023–2031 (USD MILLION) 152.
TABLE 127 CRISPR MARKET, BY APPLICATION, 2023–2031 (USD MILLION) 154.
TABLE 128 CRISPR MARKET FOR DRUG DISCOVERY & DEVELOPMENT APPLICATIONS,.
BY REGION, 2023–2031 (USD MILLION) 155.
TABLE 129 NORTH AMERICA: CRISPR MARKET FOR DRUG DISCOVERY & DEVELOPMENT APPLICATIONS, BY COUNTRY, 2023–2031 (USD MILLION) 155.
TABLE 130 EUROPE: CRISPR MARKET FOR DRUG DISCOVERY & DEVELOPMENT APPLICATIONS, BY COUNTRY, 2023–2031 (USD MILLION) 156.
TABLE 131 ASIA PACIFIC: CRISPR MARKET FOR DRUG DISCOVERY & DEVELOPMENT APPLICATIONS, BY COUNTRY, 2023–2031 (USD MILLION) 156.
TABLE 132 LATIN AMERICA: CRISPR MARKET FOR DRUG DISCOVERY & DEVELOPMENT APPLICATIONS, BY COUNTRY, 2023–2031 (USD MILLION) 156.
TABLE 133 MIDDLE EAST: CRISPR MARKET FOR DRUG DISCOVERY & DEVELOPMENT APPLICATIONS, BY REGION, 2023–2031 (USD MILLION) 157.
TABLE 134 GCC COUNTRIES: CRISPR MARKET FOR DRUG DISCOVERY & DEVELOPMENT APPLICATIONS, BY COUNTRY, 2023–2031 (USD MILLION) 157.
TABLE 135 CRISPR MARKET FOR AGRICULTURAL APPLICATIONS, BY REGION,.
2023–2031 (USD MILLION) 158.
TABLE 136 NORTH AMERICA: CRISPR MARKET FOR AGRICULTURAL APPLICATIONS,.
BY COUNTRY, 2023–2031 (USD MILLION) 158.
TABLE 137 EUROPE: CRISPR MARKET FOR AGRICULTURAL APPLICATIONS, BY COUNTRY, 2023–2031 (USD MILLION) 158.
TABLE 138 ASIA PACIFIC: CRISPR MARKET FOR AGRICULTURAL APPLICATIONS, BY COUNTRY, 2023–2031 (USD MILLION) 159.
TABLE 139 LATIN AMERICA: CRISPR MARKET FOR AGRICULTURAL APPLICATIONS,.
BY COUNTRY, 2023–2031 (USD MILLION) 159.
TABLE 140 MIDDLE EAST: CRISPR MARKET FOR AGRICULTURAL APPLICATIONS, BY REGION, 2023–2031 (USD MILLION) 159.
TABLE 141 GCC COUNTRIES: CRISPR MARKET FOR AGRICULTURAL APPLICATIONS,.
BY COUNTRY, 2023–2031 (USD MILLION) 160.
TABLE 142 CRISPR MARKET FOR OTHER APPLICATIONS, BY REGION,.
2023–2031 (USD MILLION) 160.
TABLE 143 NORTH AMERICA: CRISPR MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2023–2031 (USD MILLION) 161.
TABLE 144 EUROPE: CRISPR MARKET FOR OTHER APPLICATIONS, BY COUNTRY,.
2023–2031 (USD MILLION) 161.
TABLE 145 ASIA PACIFIC: CRISPR MARKET FOR OTHER APPLICATIONS, BY COUNTRY,.
2023–2031 (USD MILLION) 161.
TABLE 146 LATIN AMERICA: CRISPR MARKET FOR OTHER APPLICATIONS, BY COUNTRY,.
2023–2031 (USD MILLION) 162.
TABLE 147 MIDDLE EAST: CRISPR MARKET FOR OTHER APPLICATIONS, BY REGION,.
2023–2031 (USD MILLION) 162.
TABLE 148 GCC COUNTRIES: CRISPR MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2023–2031 (USD MILLION) 162.
TABLE 149 CRISPR MARKET, BY REGION, 2023–2031 (USD MILLION) 164.
TABLE 150 NORTH AMERICA: CRISPR MARKET, BY OFFERING, 2023–2031 (USD MILLION) 165.
TABLE 151 NORTH AMERICA: CRISPR MARKET, BY PRODUCT, 2023–2031 (USD MILLION) 166.
TABLE 152 NORTH AMERICA: CRISPR PRODUCTS MARKET, BY END USER,.
2023–2031 (USD MILLION) 166.
TABLE 153 NORTH AMERICA: CRISPR MARKET, BY SERVICE, 2023–2031 (USD MILLION) 166.
TABLE 154 NORTH AMERICA: CRISPR MARKET, BY APPLICATION, 2023–2031 (USD MILLION) 167.
TABLE 155 NORTH AMERICA: CRISPR SERVICES MARKET, BY END USER,.
2023–2031 (USD MILLION) 167.
TABLE 156 US: CRISPR MARKET, BY OFFERING, 2023–2031 (USD MILLION) 168.
TABLE 157 US: CRISPR MARKET, BY PRODUCT, 2023–2031 (USD MILLION) 168.
TABLE 158 US: CRISPR PRODUCTS MARKET, BY END USER, 2023–2031 (USD MILLION) 168.
TABLE 159 US: CRISPR MARKET, BY SERVICE, 2023–2031 (USD MILLION) 169.
TABLE 160 US: CRISPR MARKET, BY APPLICATION, 2023–2031 (USD MILLION) 169.
TABLE 161 US: CRISPR SERVICES MARKET, BY END USER, 2023–2031 (USD MILLION) 169.
TABLE 162 CANADA: CRISPR MARKET, BY OFFERING, 2023–2031 (USD MILLION) 170.
TABLE 163 CANADA: CRISPR MARKET, BY PRODUCT, 2023–2031 (USD MILLION) 170.
TABLE 164 CANADA: CRISPR PRODUCTS MARKET, BY END USER, 2023–2031 (USD MILLION) 171.
TABLE 165 CANADA: CRISPR MARKET, BY SERVICE, 2023–2031 (USD MILLION) 171.
TABLE 166 CANADA: CRISPR MARKET, BY APPLICATION, 2023–2031 (USD MILLION) 171.
TABLE 167 CANADA: CRISPR SERVICES MARKET, BY END USER, 2023–2031 (USD MILLION) 172.
TABLE 168 EUROPE: CRISPR MARKET, BY COUNTRY, 2023–2031 (USD MILLION) 172.
TABLE 169 EUROPE: CRISPR MARKET, BY OFFERING, 2023–2031 (USD MILLION) 173.
TABLE 170 EUROPE: CRISPR MARKET, BY PRODUCT, 2023–2031 (USD MILLION) 173.
TABLE 171 EUROPE: CRISPR PRODUCTS MARKET, BY END USER, 2023–2031 (USD MILLION) 173.
TABLE 172 EUROPE: CRISPR MARKET, BY SERVICE, 2023–2031 (USD MILLION) 174.
TABLE 173 EUROPE: CRISPR MARKET, BY APPLICATION, 2023–2031 (USD MILLION) 174.
TABLE 174 EUROPE: CRISPR SERVICES MARKET, BY END USER, 2023–2031 (USD MILLION) 174.
TABLE 175 GERMANY: CRISPR MARKET, BY OFFERING, 2023–2031 (USD MILLION) 175.
TABLE 176 GERMANY: CRISPR MARKET, BY PRODUCT, 2023–2031 (USD MILLION) 175.
TABLE 177 GERMANY: CRISPR PRODUCTS MARKET, BY END USER,.
2023–2031 (USD MILLION) 176.
TABLE 178 GERMANY: CRISPR MARKET, BY SERVICE, 2023–2031 (USD MILLION) 176.
TABLE 179 GERMANY: CRISPR MARKET, BY APPLICATION, 2023–2031 (USD MILLION) 176.
TABLE 180 GERMANY: CRISPR SERVICES MARKET, BY END USER, 2023–2031 (USD MILLION) 177.
TABLE 181 UK: CRISPR MARKET, BY OFFERING, 2023–2031 (USD MILLION) 177.
TABLE 182 UK: CRISPR MARKET, BY PRODUCT, 2023–2031 (USD MILLION) 178.
TABLE 183 UK: CRISPR PRODUCTS MARKET, BY END USER, 2023–2031 (USD MILLION) 178.
TABLE 184 UK: CRISPR MARKET, BY SERVICE, 2023–2031 (USD MILLION) 178.
TABLE 185 UK: CRISPR MARKET, BY APPLICATION, 2023–2031 (USD MILLION) 179.
TABLE 186 UK: CRISPR SERVICES MARKET, BY END USER, 2023–2031 (USD MILLION) 179.
TABLE 187 FRANCE: CRISPR MARKET, BY OFFERING, 2023–2031 (USD MILLION) 180.
TABLE 188 FRANCE: CRISPR MARKET, BY PRODUCT, 2023–2031 (USD MILLION) 180.
TABLE 189 FRANCE: CRISPR PRODUCTS MARKET, BY END USER, 2023–2031 (USD MILLION) 180.
TABLE 190 FRANCE: CRISPR MARKET, BY SERVICE, 2023–2031 (USD MILLION) 181.
TABLE 191 FRANCE: CRISPR MARKET, BY APPLICATION, 2023–2031 (USD MILLION) 181.
TABLE 192 FRANCE: CRISPR SERVICES MARKET, BY END USER, 2023–2031 (USD MILLION) 181.
TABLE 193 ITALY: CRISPR MARKET, BY OFFERING, 2023–2031 (USD MILLION) 182.
TABLE 194 ITALY: CRISPR MARKET, BY PRODUCT, 2023–2031 (USD MILLION) 183.
TABLE 195 ITALY: CRISPR PRODUCTS MARKET, BY END USER, 2023–2031 (USD MILLION) 183.
TABLE 196 ITALY: CRISPR MARKET, BY SERVICE, 2023–2031 (USD MILLION) 183.
TABLE 197 ITALY: CRISPR MARKET, BY APPLICATION, 2023–2031 (USD MILLION) 184.
TABLE 198 ITALY: CRISPR SERVICES MARKET, BY END USER, 2023–2031 (USD MILLION) 184.
TABLE 199 SPAIN: CRISPR MARKET, BY OFFERING, 2023–2031 (USD MILLION) 185.
TABLE 200 SPAIN: CRISPR MARKET, BY PRODUCT, 2023–2031 (USD MILLION) 185.
TABLE 201 SPAIN: CRISPR PRODUCTS MARKET, BY END USER, 2023–2031 (USD MILLION) 185.
TABLE 202 SPAIN: CRISPR MARKET, BY SERVICE, 2023–2031 (USD MILLION) 186.
TABLE 203 SPAIN: CRISPR MARKET, BY APPLICATION, 2023–2031 (USD MILLION) 186.
TABLE 204 SPAIN: CRISPR SERVICES MARKET, BY END USER, 2023–2031 (USD MILLION) 186.
TABLE 205 REST OF EUROPE: CRISPR MARKET, BY OFFERING, 2023–2031 (USD MILLION) 187.
TABLE 206 REST OF EUROPE: CRISPR MARKET, BY PRODUCT, 2023–2031 (USD MILLION) 187.
TABLE 207 REST OF EUROPE: CRISPR MARKET, BY SERVICE, 2023–2031 (USD MILLION) 187.
TABLE 208 REST OF EUROPE: CRISPR PRODUCTS MARKET, BY END USER,.
2023–2031 (USD MILLION) 188.
TABLE 209 REST OF EUROPE: CRISPR MARKET, BY APPLICATION, 2023–2031 (USD MILLION) 188.
TABLE 210 REST OF EUROPE: CRISPR SERVICES MARKET, BY END USER,.
2023–2031 (USD MILLION) 188.
TABLE 211 ASIA PACIFIC: CRISPR MARKET, BY COUNTRY, 2023–2031 (USD MILLION) 190.
TABLE 212 ASIA PACIFIC: CRISPR MARKET, BY OFFERING, 2023–2031 (USD MILLION) 190.
TABLE 213 ASIA PACIFIC: CRISPR MARKET, BY PRODUCT, 2023–2031 (USD MILLION) 190.
TABLE 214 ASIA PACIFIC: CRISPR PRODUCTS MARKET, BY END USER,.
2023–2031 (USD MILLION) 191.
TABLE 215 ASIA PACIFIC: CRISPR MARKET, BY SERVICE, 2023–2031 (USD MILLION) 191.
TABLE 216 ASIA PACIFIC: CRISPR MARKET, BY APPLICATION, 2023–2031 (USD MILLION) 191.
TABLE 217 ASIA PACIFIC: CRISPR SERVICES MARKET, BY END USER,.
2023–2031 (USD MILLION) 192.
TABLE 218 CHINA: CRISPR MARKET, BY OFFERING, 2023–2031 (USD MILLION) 193.
TABLE 219 CHINA: CRISPR MARKET, BY PRODUCT, 2023–2031 (USD MILLION) 193.
TABLE 220 CHINA: CRISPR PRODUCTS MARKET, BY END USER, 2023–2031 (USD MILLION) 193.
TABLE 221 CHINA: CRISPR MARKET, BY SERVICE, 2023–2031 (USD MILLION) 194.
TABLE 222 CHINA: CRISPR MARKET, BY APPLICATION, 2023–2031 (USD MILLION) 194.
TABLE 223 CHINA: CRISPR SERVICES MARKET, BY END USER, 2023–2031 (USD MILLION) 194.
TABLE 224 JAPAN: CRISPR MARKET, BY OFFERING, 2023–2031 (USD MILLION) 195.
TABLE 225 JAPAN: CRISPR MARKET, BY PRODUCT, 2023–2031 (USD MILLION) 195.
TABLE 226 JAPAN: CRISPR PRODUCTS MARKET, BY END USER, 2023–2031 (USD MILLION) 196.
TABLE 227 JAPAN: CRISPR MARKET, BY SERVICE, 2023–2031 (USD MILLION) 196.
TABLE 228 JAPAN: CRISPR MARKET, BY APPLICATION, 2023–2031 (USD MILLION) 196.
TABLE 229 JAPAN: CRISPR SERVICES MARKET, BY END USER, 2023–2031 (USD MILLION) 197.
TABLE 230 INDIA: CRISPR MARKET, BY OFFERING, 2023–2031 (USD MILLION) 198.
TABLE 231 INDIA: CRISPR MARKET, BY PRODUCT, 2023–2031 (USD MILLION) 198.
TABLE 232 INDIA: CRISPR PRODUCTS MARKET, BY END USER, 2023–2031 (USD MILLION) 198.
TABLE 233 INDIA: CRISPR MARKET, BY SERVICE, 2023–2031 (USD MILLION) 199.
TABLE 234 INDIA: CRISPR MARKET, BY APPLICATION, 2023–2031 (USD MILLION) 199.
TABLE 235 INDIA: CRISPR SERVICES MARKET, BY END USER, 2023–2031 (USD MILLION) 199.
TABLE 236 AUSTRALIA: CRISPR MARKET, BY OFFERING, 2023–2031 (USD MILLION) 200.
TABLE 237 AUSTRALIA: CRISPR MARKET, BY PRODUCT, 2023–2031 (USD MILLION) 200.
TABLE 238 AUSTRALIA: CRISPR PRODUCTS MARKET, BY END USER,.
2023–2031 (USD MILLION) 201.
TABLE 239 AUSTRALIA: CRISPR MARKET, BY SERVICE, 2023–2031 (USD MILLION) 201.
TABLE 240 AUSTRALIA: CRISPR MARKET, BY APPLICATION, 2023–2031 (USD MILLION) 201.
TABLE 241 AUSTRALIA: CRISPR SERVICES MARKET, BY END USER,.
2023–2031 (USD MILLION) 202.
TABLE 242 SOUTH KOREA: CRISPR MARKET, BY OFFERING, 2023–2031 (USD MILLION) 202.
TABLE 243 SOUTH KOREA: CRISPR MARKET, BY PRODUCT, 2023–2031 (USD MILLION) 203.
TABLE 244 SOUTH KOREA: CRISPR PRODUCTS MARKET, BY END USER,.
2023–2031 (USD MILLION) 203.
TABLE 245 SOUTH KOREA: CRISPR MARKET, BY SERVICE, 2023–2031 (USD MILLION) 203.
TABLE 246 SOUTH KOREA: CRISPR MARKET, BY APPLICATION, 2023–2031 (USD MILLION) 204.
TABLE 247 SOUTH KOREA: CRISPR SERVICES MARKET, BY END USER,.
2023–2031 (USD MILLION) 204.
TABLE 248 REST OF ASIA PACIFIC: CRISPR MARKET, BY OFFERING,.
2023–2031 (USD MILLION) 204.
TABLE 249 REST OF ASIA PACIFIC: CRISPR MARKET, BY PRODUCT,.
2023–2031 (USD MILLION) 205.
TABLE 250 REST OF ASIA PACIFIC: CRISPR PRODUCTS MARKET, BY END USER,.
2023–2031 (USD MILLION) 205.
TABLE 251 REST OF ASIA PACIFIC: CRISPR MARKET, BY SERVICE, 2023–2031 (USD MILLION) 205.
TABLE 252 REST OF ASIA PACIFIC: CRISPR MARKET, BY APPLICATION,.
2023–2031 (USD MILLION) 206.
TABLE 253 REST OF ASIA PACIFIC: CRISPR SERVICES MARKET, BY END USER,.
2023–2031 (USD MILLION) 206.
TABLE 254 LATIN AMERICA: CRISPR MARKET, BY COUNTRY, 2023–2031 (USD MILLION) 207.
TABLE 255 LATIN AMERICA: CRISPR MARKET, BY OFFERING, 2023–2031 (USD MILLION) 207.
TABLE 256 LATIN AMERICA: CRISPR MARKET, BY PRODUCT, 2023–2031 (USD MILLION) 207.
TABLE 257 LATIN AMERICA: CRISPR PRODUCTS MARKET, BY END USER,.
2023–2031 (USD MILLION) 208.
TABLE 258 LATIN AMERICA: CRISPR MARKET, BY SERVICE, 2023–2031 (USD MILLION) 208.
TABLE 259 LATIN AMERICA: CRISPR MARKET, BY APPLICATION, 2023–2031 (USD MILLION) 208.
TABLE 260 LATIN AMERICA: CRISPR SERVICES MARKET, BY END USER,.
2023–2031 (USD MILLION) 209.
TABLE 261 BRAZIL: CRISPR MARKET, BY OFFERING, 2023–2031 (USD MILLION) 209.
TABLE 262 BRAZIL: CRISPR MARKET, BY PRODUCT, 2023–2031 (USD MILLION) 210.
TABLE 263 BRAZIL: CRISPR PRODUCTS MARKET, BY END USER, 2023–2031 (USD MILLION) 210.
TABLE 264 BRAZIL: CRISPR MARKET, BY SERVICE, 2023–2031 (USD MILLION) 210.
TABLE 265 BRAZIL: CRISPR MARKET, BY APPLICATION, 2023–2031 (USD MILLION) 211.
TABLE 266 BRAZIL: CRISPR SERVICES MARKET, BY END USER, 2023–2031 (USD MILLION) 211.
TABLE 267 REST OF LATIN AMERICA: CRISPR MARKET, BY OFFERING,.
2023–2031 (USD MILLION) 211.
TABLE 268 REST OF LATIN AMERICA: CRISPR MARKET, BY PRODUCT,.
2023–2031 (USD MILLION) 212.
TABLE 269 REST OF LATIN AMERICA: CRISPR PRODUCTS MARKET, BY END USER,.
2023–2031 (USD MILLION) 212.
TABLE 270 REST OF LATIN AMERICA: CRISPR MARKET, BY SERVICE,.
2023–2031 (USD MILLION) 212.
TABLE 271 REST OF LATIN AMERICA: CRISPR MARKET, BY APPLICATION,.
2023–2031 (USD MILLION) 213.
TABLE 272 REST OF LATIN AMERICA: CRISPR SERVICES MARKET, BY END USER,.
2023–2031 (USD MILLION) 213.
TABLE 273 MIDDLE EAST: CRISPR MARKET, BY REGION, 2023–2031 (USD MILLION) 214.
TABLE 274 MIDDLE EAST: CRISPR MARKET, BY OFFERING, 2023–2031 (USD MILLION) 214.
TABLE 275 MIDDLE EAST: CRISPR MARKET, BY PRODUCT, 2023–2031 (USD MILLION) 214.
TABLE 276 MIDDLE EAST: CRISPR PRODUCTS MARKET, BY END USER,.
2023–2031 (USD MILLION) 215.
TABLE 277 MIDDLE EAST: CRISPR MARKET, BY SERVICE, 2023–2031 (USD MILLION) 215.
TABLE 278 MIDDLE EAST: CRISPR MARKET, BY APPLICATION, 2023–2031 (USD MILLION) 215.
TABLE 279 MIDDLE EAST: CRISPR SERVICES MARKET, BY END USER,.
2023–2031 (USD MILLION) 216.
TABLE 280 GCC COUNTRIES: CRISPR MARKET, BY COUNTRY, 2023–2031 (USD MILLION) 216.
TABLE 281 GCC COUNTRIES: CRISPR MARKET, BY OFFERING, 2023–2031 (USD MILLION) 217.
TABLE 282 GCC COUNTRIES: CRISPR MARKET, BY PRODUCT, 2023–2031 (USD MILLION) 217.
TABLE 283 GCC COUNTRIES: CRISPR PRODUCTS MARKET, BY END USER,.
2023–2031 (USD MILLION) 217.
TABLE 284 GCC COUNTRIES: CRISPR MARKET, BY SERVICE, 2023–2031 (USD MILLION) 218.
TABLE 285 GCC COUNTRIES: CRISPR MARKET, BY APPLICATION, 2023–2031 (USD MILLION) 218.
TABLE 286 GCC COUNTRIES: CRISPR SERVICES MARKET, BY END USER,.
2023–2031 (USD MILLION) 218.
TABLE 287 SAUDI ARABIA: CRISPR MARKET, BY OFFERING, 2023–2031 (USD MILLION) 219.
TABLE 288 SAUDI ARABIA: CRISPR MARKET, BY PRODUCT, 2023–2031 (USD MILLION) 219.
TABLE 289 SAUDI ARABIA: CRISPR PRODUCTS MARKET, BY END USER,.
2023–2031 (USD MILLION) 220.
TABLE 290 SAUDI ARABIA: CRISPR MARKET, BY SERVICE, 2023–2031 (USD MILLION) 220.
TABLE 291 SAUDI ARABIA: CRISPR MARKET, BY APPLICATION, 2023–2031 (USD MILLION) 220.
TABLE 292 SAUDI ARABIA: CRISPR SERVICES MARKET, BY END USER,.
2023–2031 (USD MILLION) 221.
TABLE 293 UAE: CRISPR MARKET, BY OFFERING, 2023–2031 (USD MILLION) 221.
TABLE 294 UAE: CRISPR MARKET, BY PRODUCT, 2023–2031 (USD MILLION) 222.
TABLE 295 UAE: CRISPR PRODUCTS MARKET, BY END USER, 2023–2031 (USD MILLION) 222.
TABLE 296 UAE: CRISPR MARKET, BY SERVICE, 2023–2031 (USD MILLION) 222.
TABLE 297 UAE: CRISPR MARKET, BY APPLICATION, 2023–2031 (USD MILLION) 223.
TABLE 298 UAE: CRISPR SERVICES MARKET, BY END USER, 2023–2031 (USD MILLION) 223.
TABLE 299 REST OF GCC COUNTRIES: CRISPR MARKET, BY OFFERING,.
2023–2031 (USD MILLION) 224.
TABLE 300 REST OF GCC COUNTRIES: CRISPR MARKET, BY PRODUCT,.
2023–2031 (USD MILLION) 224.
TABLE 301 REST OF GCC COUNTRIES: CRISPR PRODUCTS MARKET, BY END USER,.
2023–2031 (USD MILLION) 224.
TABLE 302 REST OF GCC COUNTRIES: CRISPR MARKET, BY SERVICE,.
2023–2031 (USD MILLION) 225.
TABLE 303 REST OF GCC COUNTRIES: CRISPR MARKET, BY APPLICATION,.
2023–2031 (USD MILLION) 225.
TABLE 304 REST OF GCC COUNTRIES: CRISPR SERVICES MARKET, BY END USER,.
2023–2031 (USD MILLION) 225.
TABLE 305 REST OF MIDDLE EAST: CRISPR MARKET, BY OFFERING,.
2023–2031 (USD MILLION) 226.
TABLE 306 REST OF MIDDLE EAST: CRISPR MARKET, BY PRODUCT,.
2023–2031 (USD MILLION) 226.
TABLE 307 REST OF MIDDLE EAST: CRISPR PRODUCTS MARKET, BY END USER,.
2023–2031 (USD MILLION) 227.
TABLE 308 REST OF MIDDLE EAST: CRISPR MARKET, BY SERVICE, 2023–2031 (USD MILLION) 227.
TABLE 309 REST OF MIDDLE EAST: CRISPR MARKET, BY APPLICATION,.
2023–2031 (USD MILLION) 227.
TABLE 310 REST OF MIDDLE EAST: CRISPR SERVICES MARKET, BY END USER,.
2023–2031 (USD MILLION) 228.
TABLE 311 AFRICA: CRISPR MARKET, BY OFFERING, 2023–2031 (USD MILLION) 228.
TABLE 312 AFRICA: CRISPR MARKET, BY PRODUCT, 2023–2031 (USD MILLION) 229.
TABLE 313 AFRICA: CRISPR PRODUCTS MARKET, BY END USER, 2023–2031 (USD MILLION) 229.
TABLE 314 AFRICA: CRISPR MARKET, BY SERVICE, 2023–2031 (USD MILLION) 229.
TABLE 315 AFRICA: CRISPR MARKET, BY APPLICATION, 2023–2031 (USD MILLION) 230.
TABLE 316 AFRICA: CRISPR SERVICES MARKET, BY END USER, 2023–2031 (USD MILLION) 230.
TABLE 317 STRATEGIES ADOPTED BY KEY PLAYERS IN CRISPR MARKET,.
JANUARY 2023–SEPTEMBER 2026 231.
TABLE 318 CRISPR MARKET: DEGREE OF COMPETITION 234.
TABLE 319 CRISPR MARKET: REGION FOOTPRINT 237.
TABLE 320 CRISPR MARKET: PRODUCT FOOTPRINT 238.
TABLE 321 CRISPR MARKET: SERVICE FOOTPRINT 238.
TABLE 322 CRISPR MARKET: APPLICATION FOOTPRINT 239.
TABLE 323 CRISPR MARKET: DETAILED LIST OF KEY STARTUPS/SMES 242.
TABLE 324 CRISPR MARKET: COMPETITIVE BENCHMARKING OF KEY STARTUPS/SMES 243.
TABLE 325 CRISPR MARKET: PRODUCT LAUNCHES, JANUARY 2023–SEPTEMBER 2026 246.